Incretin Atlas › Trials › DREAMS-1
DREAMS-1
Mazdutide · t2d
Design
- Molecule(s)
- Mazdutide
- Population
- t2d
- Phase
- 3
- Participants
- 320
- Duration
- 24 weeks
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 mg | t2d china | 24 | 320 | — | −5.5 % vs −1.1 % Δ −4.3 pp | −1.6 vs −0.2 | — | — | — | — | — | — | press release |
| 6 mg | t2d china | 24 | 320 | — | −7.3 % vs −1.1 % Δ −6.2 pp | −2.0 vs −0.2 | — | — | — | — | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (4)
- 4 mg · hba1c · press release
the adjusted least-squares (LS) mean changes in HbA1c from baseline at Week 24 were -1.58% for mazdutide 4 mg, -2.02% for mazdutide 6 mg, and -0.25% for placebo, respectively
- 4 mg · weight_tp · press release
the adjusted LS mean percentage weight changes from baseline at Week 24 were -5.50% for mazdutide 4 mg, -7.34% for mazdutide 6 mg, and -1.15% for placebo, respectively
- 6 mg · hba1c · press release
the adjusted least-squares (LS) mean changes in HbA1c from baseline at Week 24 were -1.58% for mazdutide 4 mg, -2.02% for mazdutide 6 mg, and -0.25% for placebo, respectively
- 6 mg · weight_tp · press release
the adjusted LS mean percentage weight changes from baseline at Week 24 were -5.50% for mazdutide 4 mg, -7.34% for mazdutide 6 mg, and -1.15% for placebo, respectively
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: DREAMS-1. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/dreams-1/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.